Arrayit, DOCRO Sign Deal Aimed at FDA Approval | GenomeWeb

NEW YORK (GenomeWeb News) – Arrayit said today it has inked a professional services master agreement with Diagnostic Oncology Research Organization to aid it in obtaining approval from the US Food and Drug Administration for its tests.

The agreement will serve as a blueprint for submitting Arrayit's OvaDx presymptomatic ovarian cancer monitoring and screening test, a secondary Parkinson's disease diagnostic test, and other tests in the company's pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.